Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

Clin Infect Dis. 2008 Apr 1;46(7):e69-71. doi: 10.1086/529388.


The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Male
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous / microbiology*
  • Mycobacterium marinum / isolation & purification*
  • Skin / microbiology
  • Skin / pathology
  • Skin Diseases, Bacterial / microbiology*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use


  • Antineoplastic Agents
  • Thalidomide
  • Lenalidomide